Triptorelin pamoate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100894

CAS#: 124508-66-3 (pamoate)

Description: Triptorelin, a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), is a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts. By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. It is also used as therapy for gender identity disorder.

Chemical Structure

Triptorelin pamoate
CAS# 124508-66-3 (pamoate)

Theoretical Analysis

MedKoo Cat#: 100894
Name: Triptorelin pamoate
CAS#: 124508-66-3 (pamoate)
Chemical Formula: C87H98N18O19
Exact Mass:
Molecular Weight: 1699.85
Elemental Analysis: C, 61.47; H, 5.81; N, 14.83; O, 17.88

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Related CAS #: 140194-24-7 (acetate)   57773-63-4 (free base)   124508-66-3 (pamoate)    

Synonym: AY25650; AY-25650; AY 25650; CL118532; CL-118532; CL 118532; Wy42462; Wy-42462; Wy4 2462; D-Trp-6-LH-RH; Triptorelin. US brand name: Trelstar Depot. Decapeptyl; Decapeptyl Depot; Decapeptyl LP; Decapeptyl Trimestral; Embonate.

IUPAC/Chemical Name: (S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6,15-bis((1H-indol-3-yl)methyl)-21-(3-((diaminomethylene)amino)propyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide 4,4'-methylenebis(3-hydroxy-2-naphthoate)


InChi Code: InChI=1S/C64H82N18O13.C23H16O6/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44;24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69);1-10,24-25H,11H2,(H,26,27)(H,28,29)/t44-,45-,46-,47-,48+,49-,50-,51-,52-;/m0./s1

SMILES Code: CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1699.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundström E, Purcea D, Cassorla F. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016 Feb 17. pii: /j/jpem.ahead-of-print/jpem-2015-0376/jpem-2015-0376.xml. doi: 10.1515/jpem-2015-0376. [Epub ahead of print] PubMed PMID: 26887034.

2: Meattini I, Saieva C, Meacci F, Scotti V, De Luca Cardillo C, Desideri I, Baldazzi V, Mangoni M, Scoccianti S, Detti B, Simontacchi G, Nori J, Orzalesi L, Sanchez L, Casella D, Bernini M, Fambrini M, Bianchi S, Livi L. Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin. Future Oncol. 2016 Mar;12(5):625-35. doi: 10.2217/fon.15.357. Epub 2016 Feb 3. PubMed PMID: 26837239.

3: Bellet M, Gray KP, Francis PA, Láng I, Ciruelos E, Lluch A, Climent MA, Catalán G, Avella A, Bohn U, González-Martin A, Ferrer R, Catalán R, Azaro A, Rajasekaran A, Morales J, Vázquez J, Fleming GF, Price KN, Regan MM. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016 Jan 4. pii: JCO612259. [Epub ahead of print] PubMed PMID: 26729437.

4: Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; GIM Study Group. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. JAMA. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291. PubMed PMID: 26720025.

5: Freire AV, Gryngarten MG, Ballerini MG, Arcari AJ, Escobar ME, Bergadá I, Ropelato MG. Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty. Horm Res Paediatr. 2016;85(1):58-64. doi: 10.1159/000442523. Epub 2015 Dec 17. PubMed PMID: 26675317.

6: Wang Y, Tian X, Liang L, Wang Y, Wang R, Cheng X, Yan Z, Chen Y, Qi P. Mechanistic Study on Triptorelin Action in Protecting From 5-FU-Induced Ovarian Damage in Rats. Oncol Res. 2015;22(5):283-92. doi: 10.3727/096504015X14410238486720. PubMed PMID: 26629940.

7: Caruso M, Castiglione G, Aiello R, Alí M, Chiarenza M, Dimarco R, Fallica G, Di Leo MG, Sanó MV, Taibi E, Zacchia A, Miano E, Caruso F. 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience. Future Oncol. 2015 Dec;11(23):3109-12. doi: 10.2217/fon.15.261. Epub 2015 Nov 6. PubMed PMID: 26544787.

8: Cornford P, Jefferson K, Cole O, Gilbody JS, Nayar V, Auddy G. Switching to A 6-Monthly Triptorelin Formulation for Prostate Cancer (Pca) Reduces Patient-Nhs Interactions and Hospital Resource use: Real World Evidence (Rwe) from Project Deserve (Decapeptyl Service Evaluation). Value Health. 2015 Nov;18(7):A483. doi: 10.1016/j.jval.2015.09.1319. Epub 2015 Oct 20. PubMed PMID: 26532711.

9: Bertelloni S, Massart F, Einaudi S, Wasniewska M, Miccoli M, Baroncelli GI. Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin. Horm Res Paediatr. 2015;84(6):396-400. doi: 10.1159/000441497. Epub 2015 Nov 4. PubMed PMID: 26528763.

10: Darwish B, Leleup G, Martin C, Roman H. Our experience with long-term triptorelin therapy in a large endometriosis nodule arising in an episiotomy scar. Gynecol Obstet Fertil. 2015 Nov;43(11):757-8. doi: 10.1016/j.gyobfe.2015.09.008. Epub 2015 Oct 17. PubMed PMID: 26482835.

11: Fazeli F, Nowroozi MR, Ayati M, Latifi S, Taheri Mahmoodi M, Norouzi Javidan A, Jamshidian H, Arbab A. Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial. Nephrourol Mon. 2015 May 25;7(3):e27107. doi: 10.5812/numonthly.7(3)2015.27107. eCollection 2015 May. PubMed PMID: 26290848; PubMed Central PMCID: PMC4537641.

12: Roman H, Saint Ghislain M, Milles M, Marty N, Hennetier C, Moatassim S, Desnyder E, Abo C. Improvement of digestive complaints in women with severe colorectal endometriosis benefiting from continuous amenorrhoea triggered by triptorelin. A prospective pilot study. Gynecol Obstet Fertil. 2015 Sep;43(9):575-81. doi: 10.1016/j.gyobfe.2015.07.001. Epub 2015 Jul 30. PubMed PMID: 26234686.

13: Guerrero-Pérez F, Marengo AP, Planas-Vilaseca A, Flores-Escobar V, Villabona-Artero C. Pituitary apoplexy induced by triptorelin in patient with prostate cancer. Endocrinol Nutr. 2015 Oct;62(8):411-2. doi: 10.1016/j.endonu.2015.05.005. Epub 2015 Jul 13. English, Spanish. PubMed PMID: 26184059.

14: Lebret T, Rouanne M, Hublarov O, Jinga V, Petkova L, Kotsev R, Sinescu I, Dutailly P. Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. Ther Adv Urol. 2015 Jun;7(3):125-34. doi: 10.1177/1756287215577329. PubMed PMID: 26161143; PubMed Central PMCID: PMC4485417.

15: Gil T, Aoun F, Cabri P, Maisonobe P, van Velthoven R. A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer. Ther Adv Urol. 2015 Jun;7(3):116-24. doi: 10.1177/1756287215574480. PubMed PMID: 26161142; PubMed Central PMCID: PMC4485414.

16: Bizzarri N, Ghirardi V, Remorgida V, Venturini PL, Ferrero S. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol. 2015 Sep;192:22-6. doi: 10.1016/j.ejogrb.2015.06.018. Epub 2015 Jun 25. PubMed PMID: 26142912.

17: Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet. 2015 Dec;292(6):1267-71. doi: 10.1007/s00404-015-3755-5. Epub 2015 May 20. PubMed PMID: 25990480.

18: Tkalia IG, Vorobyova LI, Grabovoy AN, Svintsitsky VS, Tarasova TO. The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats. Exp Oncol. 2015 Mar;37(1):30-5. PubMed PMID: 25804228.

19: Peltier A, Aoun F, De Ruyter V, Cabri P, Van Velthoven R. Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study. Prostate Cancer. 2015;2015:978194. doi: 10.1155/2015/978194. Epub 2015 Jan 28. PubMed PMID: 25694830; PubMed Central PMCID: PMC4324912.

20: Brunner HI, Silva CA, Reiff A, Higgins GC, Imundo L, Williams CB, Wallace CA, Aikawa NE, Nelson S, Klein-Gitelman MS, Rose SR. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2015 May;67(5):1377-85. doi: 10.1002/art.39024. PubMed PMID: 25676588; PubMed Central PMCID: PMC4414812.

Additional Information

Triptorelin (free base)
Chemical Formula: C64H82N18O13
Exact Mass: 1310.6309
Molecular Weight: 1311.4730
Elemental Analysis: C, 58.61; H, 6.30; N, 19.22; O, 15.86

CAS# related to Triptorelin
Triptorelin free base: CAS#57773-63-4
Triptorelin acetate: CAS#140194-24-7
Triptorelin pamoate: CAS#124508-66-3